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Empowerment Through Registries,
Data, and Our MembersPatrick O’Gara, MD, FACC, ACC President,
Robert A. Harrington, MD, FACC, ACC Board of TrusteesC linical research provides the evidence basefor American College of Cardiology (ACC)documents that help guide clinical practice,
including expert consensus documents, guidelines,
performance measures, and appropriate use criteria.
It has been acknowledged that clinical research is
critical for the advancement of clinical practice, and
increasingly, policy makers are looking to data from
clinical research to help inform and guide public
policy (1). Cardiology is truly an evidence-based spe-
cialty, yet only a minority of practice guideline rec-
ommendations is actually supported by the highest
quality level of evidence (2). Part of the reason for
this discrepancy is due to the many challenges associ-
ated with the conduct of clinical research, especially
in real-world situations among heterogeneous patient
populations. Clinical research has become increasingly
complex, expensive, and difﬁcult to integrate into
clinical care (3).
The clinical research workforce depends on assem-
bling teams of clinicians, quantitative scientists
(including epidemiologists, informaticians, and bio-
statisticians), as well as technical, ﬁnancial, and oper-
ational professionals. Of note, many post-graduate
residency and fellowship training programs are not
focused on training translational and clinical in-
vestigators, and somewhat surprisingly, there is both
an insufﬁcient and overly complex clinical research
infrastructure at most academic medical centers.
Although there is increasing adoption of electronic
health record (EHR) systems across both private and
academic healthcare systems, there is a notable.lack of technology infrastructure as well as clinical
data standards that would facilitate clinical research
connections among multiple institutions and in-
vestigators. Additionally, there has been little na-
tional investment into the creation and ongoing
support of sustaining investigator networks, which
means that most clinical research projects require
building a network each and every time. This is costly
and fraught with delays and inefﬁciencies. Finally,
with constraints on public research funding mecha-
nisms, there is a great need for more research col-
laborations among academics, private practitioners,
and private industry. But intense media coverage of
issues such as conﬂict of interest and relationships
with industry has dissuaded many from joining and
participating in the research process.
A paradox of contemporary society is our ever-
increasing demand for evidence to guide clinical
practice and decision making while we simulta-
neously struggle to perform the practical aspects of
clinical research. Michael Lauer, MD, Director of the
Division of Cardiovascular Sciences at the National
Heart, Lung, and Blood Institute, and his colleagues
have called for disruption in the conduct of clinical
research and have emphasized the need to both
increase the volume of clinical investigation while
also markedly improving the efﬁciency and ulti-
mately the output of this investigation (4). They and
others have called for better use of EHRs and other
large, coordinated datasets for both more sophisti-
cated observational outcomes research as well as the
conduct of pragmatic clinical trials, including use
of innovative methods such as EHR point-of-care
randomization and registry-based randomized clin-
ical trials (5). One could argue that the ability to
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most critical aspects of research today.
In the midst of these societal challenges, the ACC is
well suited to play a major leadership role in these
needed disruptions, while also providing real and
tangible member beneﬁts. Improving the nation’s
clinical research enterprise is completely aligned with
and supportive of the College’s mission to “transform
cardiovascular care and improve heart health” as
well as its principle to “promote growth, dissemina-
tion and application of knowledge about cardiovas-
cular medicine.” The investments in building the
National Cardiovascular Data Registry (NCDR) over
more than a decade will now position us to carry out
our recently crafted strategic plan that focuses on
increasing the effectiveness of each member, facili-
tating care transformation, improving population
health, providing purposeful education, shaping
health policy through more focused advocacy, and
leveraging data and information to improve knowl-
edge and practice.
The College, including in its partnership with the
American Heart Association, needs to support the full
spectrum of science, from basic discovery up through
population health science. This can be done in part
through the College’s advocacy for research funding
at the federal level as well as its continued support for
clinical research that utilizes the College’s clinical
practice registries. The College has made scholarly
activities a required component of cardiovascular
fellowship training. This will be made explicit in the
upcoming revised COCATS (Core Cardiology Training
Symposium) document. Such a requirement should
help expand the pool of clinical investigators as well
as help facilitate the interactions between basic sci-
entists and clinicians, a desperately needed compo-
nent of translational research.
Likewise, the College’s commitment to the car-
diovascular care team provides great role modeling
for the multidisciplinary teams required in clinical
investigation. The NCDR provides rich data sources
for comparative effectiveness research as well asimplementation science. The organizational structure
required to support the data registries is well suited
for helping practices and health systems organize
their own clinical research operational infrastruc-
tures. NCDR-derived analyses can serve as support
for event-rate estimates or for details on medication
usages or contemporary practice patterns needed in
the planning of randomized clinical trials.
Recently, colleagues in Sweden have shown how to
conduct a randomized clinical trial within their own
country-wide cardiovascular registries (5). Likewise,
the College has collaborated with member investi-
gators (and with support from the National Heart,
Lung, and Blood Institute) to pilot use of the CathPCI
Registry as the data collection backbone of a ran-
domized clinical trial comparing radial and femoral
access in women undergoing cardiac catheterization
(6). In using the NCDR for clinical investigation, the
College has made contributions to the creation of data
standards in cardiovascular disease, and a series of
documents has been created on data standards that
can be used to facilitate the exchange of healthcare
data. Finally, the College’s growth in international
activities provides additional opportunities for global
research collaborations among our many members
and institutions.
In summary, the thoughtful and appropriate prac-
tice of cardiovascular medicine requires an ongoing
commitment to the generation of new knowledge
through discovery and clinical investigation. There
are additional insights to be gained by facilitating
comparative effectiveness research into disease
management. The ACC is well poised to serve our
members and society by providing needed support
and dedication to cardiovascular research. We have a
responsibility to exercise leadership in this critical
enterprise.
ADDRESS CORRESPONDENCE TO: Dr. Patrick T.
O’Gara, American College of Cardiology, 2400 N
Street NW, Washington, DC 20037. E-mail: president@
acc.org.RE F E RENCE S1. Antman EM, Harrington RA. Transforming clin-
ical trials in cardiovascular disease: mission critical
for health and economic well-being. JAMA 2012;
308:1743–4.
2. Tricoci P, Allen JM, Kramer JM, Califf RM,
Smith SC. Scientiﬁc evidence underlying the ACC/
AHA Clinical Practice Guidelines. JAMA 2009;301:
831–41.
3. Eapen ZJ, Vavalle JP, Granger CB,
Harrington RA, Peterson ED, Califf RM.Rescuing clinical trials in the United States and
beyond: a call for action. Am Heart J 2013;165:
837–47.
4. Gordon D, Taddei-Peters W, Mascette A,
Antman M, Kaufmann PG, Lauer MS. Publication
of trials funded by the National Heart, Lung,
and Blood Institute. N Engl J Med 2013;369:
1926–34.
5. Fröbert O, Lagerqvist B, Olivecrona GK, et al.
Thrombus aspiration during ST-segment elevationmyocardial infarction. N Engl J Med 2013;369:
1587–97.
6. Rao SV, Hess CN, Barham B, et al.
A registry-based randomized trial comparing
radial and femoral approaches in women
undergoing percutaneous coronary interven-
tion: the SAFE-PCI for Women (Study of
Access Site for Enhancement of PCI for
Women) trial. J Am Coll Cardiol Intv 2014;7:
857–67.
